

Unusual Reaction of 4-[(3-Carboxypropyl)amino]-6-chloro-5-nitrobenzofuroxan with 3-Aminopropane-1,2-diol 1,2-Dinitrate

E. A. Chugunova^a, R. E. Mukhamatdinova^b, I. V. Serkov^c,
S. V. Kharlamov^a, A. B. Dobrynin^a, and A. R. Burilov^a

^a Arbuzov Institute of Organic and Physical Chemistry, Kazan Scientific Center,
Russian Academy of Sciences, ul. Arbuzova 8, Kazan, Tatarstan, 420088 Russia
e-mail: elena-chugunova@list.ru

^b Kazan National Research Technological University, Kazan, Tatarstan, Russia

^c Institute of Physiologically Active Substances, Russian Academy of Sciences, Chernogolovka, Moscow oblast, Russia

Received March 13, 2014

Abstract—Reaction of 4-[(3-carboxypropyl)amino]-6-chloro-5-nitrobenzofuroxan with 3-aminopropane-1,2-diol 1,2-dinitrate yielded 6-chloro-5-nitro-4-(2-oxopyrrolidin-1-yl)benzofuroxan instead of the expected 6-chloro-5-nitrobenzofuroxan amino derivative.

Keywords: 4,6-dichloro-5-nitrobenzofuroxan, X-ray diffraction, 3-aminopropane-1,2-diol 1,2-dinitrate, NO-donors


DOI: 10.1134/S1070363214080192

Benzofuroxan derivatives are known for broad range of biological activity [1], including antibacterial [2], herbicidal [3], antiparasitic [4], antileukemic [5], antirheumatic [6], and vasodilator activity [7]. In this regard, benzofuroxans are of interest as synthons for preparation of biologically active heterocyclic compounds, potential NO-generating prodrugs.

We have recently described preparation of some amino derivatives of 6-chloro-5-nitrobenzofuroxan [8] (Scheme 1).


Free carboxyl groups in the molecules of **IIIa–IIIe** can serve as linker to introduce additional pharmacophore groups allowing for synthesis of new hybrid

Scheme 1.




i, MeOH, NaHCO₃, 60°C, 4 h.

Scheme 2.



i, isobutyl chloroformate, EtOAc, Et₃N, 0–4°C, 30 min; *ii*, 2-aminoethylnitrate, EtOAc, Et₃N, 20°C, 1 h.

Scheme 3.



i, isobutyl chloroformate, EtOAc, Et₃N, 0–4°C, 30 min; *ii*, 3-aminopropane-1,2-diol 1,2-dinitrate, EtOAc, Et₃N, 20°C, 1 h.

drugs. Such opportunity has been demonstrated in [8] with reaction of **IIIId** with 2-aminoethylnitrate (Scheme 2).

In this work, we used 3-amino-1,2-diol 1,2-dinitrate as pharmacophore group consisting of additional NO-donor moiety. However, attempts to obtain 6-chloro-5-nitrobenzofuroxan derivative **VII** by analogy with compound **V** [8] failed. 6-Chloro-5-nitro-4-(2-oxopyr-

rolidin-1-yl)benzofuroxan **VIII** was obtained as the major reaction product (Scheme 3).

The structure of **VIII** was confirmed by NMR spectroscopy and X-ray diffraction. The NMR spectra contained two sets of broadened signals corresponding to two tautomers in the 7 : 3 ratio.

According to the X-ray diffraction (see Figure), the unit cell of compound **VIII** contained two independent molecules, differing in arrangement of the C¹³ and C¹⁴ atoms in the oxopyrrolidine fragment. The bond lengths were close to the usual values. Intermolecular interactions led to formation of complex three-dimensional structure.


EXPERIMENTAL

¹H NMR spectra were recorded with the Bruker AVANCE-600 spectrometer (600.13 MHz) relative to the signals of residual solvent protons (acetone-*d*₆). Melting point was determined with the Boetius apparatus and reported uncorrected. TLC was performed using Silufol UV 254 plates (Kavalier).

X-Ray diffraction study was carried out at 150 K with the Bruker Smart APEX II CCD automatic diffractometer [graphitic monochromator, $\lambda(\text{MoK}\alpha) = 0.71073 \text{ \AA}$, ω -scanning, $2\theta < 54^\circ$, $R_{\text{int}} 0.021$]. Crystals of **VIII** were monoclinic, C₁₀H₇ClN₄O₅, $M 298.65$. The unit cells parameters were as follows: $a 18.992(2)$, $b 15.552(2)$, $c 7.932(1) \text{ \AA}$, $\beta 94.259(1)^\circ$, $V 2336.3(5) \text{ \AA}^3$, $Z 8$, space group $P2_1/c$, $d_{\text{calc}} 1.698 \text{ g cm}^{-3}$, $\mu 0.356 \text{ mm}^{-1}$, $F(000) 1216$. Intensity of 19452 reflections was measured {5085 independent, 4629 observed [$I > 2\sigma(I)$]}. Final refinement parameters: values of the divergence factors: $R 0.0282$, $wR_2 0.0772$, GOF 0.91. Absorption was corrected for in SADABS software [9]. The structure was solved by direct methods (SIR [10]) and refined in the isotropic-anisotropic approximation (SHELXL-97 [11]). Parameters of the hydrogen atoms were refined using the *rider* model. All calculations were performed using WinGX [12] and APEX2 [13] software. Figures and analysis of intermolecular contacts were performed taking advantage of PLATON software [14]. Crystallographic data for **IX** were deposited at the Cambridge Structural Database (CCDC 1001192).

X-Ray diffraction analysis of single crystals of compound **VIII** was performed at Department of X-ray diffraction studies, Center for Collective Use, Arbuzov Institute of Organic and Physical Chemistry, Kazan Scientific Center, Russian Academy of Sciences.

6-Chloro-5-nitro-4-(2-oxopyrrolidin-1-yl)benzofuroxan (VIII). A mixture of 2 mL of ethyl acetate, 0.080 g (0.25 mmol) of benzofuroxan **IIId**, 0.035 mL (0.25 mmol) of triethylamine and 0.035 mL



General view of the molecule of compound **VIII**.

(0.25 mmol) of isobutyl chloroformate was stirred during 30 min at 0–4°C. Then the solvent was removed in vacuum, and the residue was dissolved in 2 mL of ethyl acetate. A solution of 3-aminopropane-1,2-diol 1,2-dinitrate, prepared from 55 mg (0.30 mmol) of 2,3-bis(nitrooxy)propylammonium nitrate and 45 μL of triethylamine in 2 mL of ethyl acetate, was added to a solution of **VI** in ethyl acetate. The reaction mixture was stirred at room temperature during 1 h, and then washed sequentially with water, hydrochloric acid, and saturated aqueous solution of NaCl. The organic layer was separated, dried over anhydrous Na₂SO₄, and evaporated in vacuum. The residue was purified by chromatography on silica gel (Merck, Germany) eluting with the benzene–EtOAc mixture. Yield 74%, mp 110–112°C (hexane). ¹H NMR spectrum, δ , ppm: 2.35 s (2H, H¹³), 2.55 s (2H, H¹²), 3.78 d (2H¹⁴_{minor}, 68.3 Hz), 4.11 s (2H, H¹⁴), 7.99 s (1H, H⁷), 8.28 s (1H⁷_{minor}). ¹³C NMR spectrum, δ_c , ppm: 19.71 (C¹³), 30.08 (C¹²), 50.02 (C¹⁴), 50.33 (C¹⁴_{minor}), 110.85 (C⁹_{minor}), 113.73 (C⁷, C⁸), 119.49 (C⁷_{minor}), 122.77 (C⁴_{minor}), 125.06 (C⁴, C⁶), 128.75 (C⁶_{minor}), 147.10 (C⁵), 148.64 (C⁹, C⁵_{minor}), 150.91 (C⁸_{minor}), 174.58 (C¹¹), 175.46 (C¹¹_{minor}).

ACKNOWLEDGMENTS

This work was financially supported by Russian Foundation for Basic Research (projects no. 14-03-31365 and 12-03-97041).

REFERENCES

1. Jovené, C., Chugunova, E.A., and Goumont, R., *Mini-Rev. Med. Chem.*, 2013, vol. 13, p. 1089. DOI: 10.2174/1389557511313080001.
2. Jorge, S.D., Masunari, A., Oliveira Rangel-Yagui, C., Mesquita Pasqualoto, K.F., and Costa Tavares, L., *Bioorg. Med. Chem.*, 2009, vol. 17, p. 3028. DOI: 10.1016/j.bmc.2009.03.011.
3. Cerecetto, H., Dias, E., Di Maio, R., Gonzales, M., Pacce, S., Saenz, P., and Seoane, G., *J. Agric. Food Chem.*, 2000, vol. 48, p. 2995. DOI: 10.1021/jf9904766.
4. Hotez, P., Molyneux, D.H., Fenwick, A., Ottesen, E., Kumaresan, J., Savioli, L., Sachs, S.E., and Sachs, J.D., *N. Engl. J. Med.*, 2007, vol. 357, p. 1018. DOI: 10.1056/NEJMra064142.
5. Ghosh, P.B. and Whitehouse, M.W., *J. Med. Chem.*, 1969, vol. 12, p. 505. DOI: 10.1021/jm00303a606.
6. Macphee, D.G., Robert, G.P., Ternai, B., Ghosh, P., and Stephens, R., *Chem.-Biol. Interact.*, 1977, vol. 19, p. 77. DOI: 10.1016/0009-2797(77)90043-6.
7. Ghosh, P.B. and Everitt, B., *J. Med. Chem.*, 1974, vol. 17, p. 203. DOI: 10.1021/jm00248a013.
8. Serkov, I.V., Chugunova, E.A., Burilov, A.R., and Bachurin, S.O., *Dokl. Chem*, 2013, vol. 450, no. 4, p. 417.
9. Sheldrick, G.M., *SADABS*, Bruker AXS Inc., Madison, USA, 1997.
10. Altomare, A., Cascarano, G., Giacovazzo, C., and Viterbo, D., *Acta Crystallogr. (A)*, 1991, vol. 47, p. 744. DOI: 10.1107/S0108767391006566.
11. Sheldrick, G.M., *SHELX-97. Programs for Crystal Structure Analysis, Release 97-2*, University of Göttingen, 1997.
12. Farrugia, L.J., *J. Appl. Crystallogr.*, 1999, vol. 32, p. 837. DOI: 10.1107/S0021889899006020.
13. *APEX2 (Version 2.1), SAINTPlus. Data Reduction and Correction Program (Version 7.31A)*, Bruker Advanced X-ray Solutions, Bruker AXS Inc., Madison, Wisconsin, USA, 2006.
14. Spek, A.L., *Acta Crystallogr. (D)*, 2009, vol. 65, p. 148.